Announced details
Treatment of patients with schizophrenia and treatment related to cognitive function
Primary endpoint theta-band measure: n=83, d=0.34, p=0.052. Subgroup with impaired cognitive function: n=59, d=0.44, p=0.03.
Alto-101 is being developed in partnership with Alto. We will discuss the detailed analysis of the trial results, including the possibility of improving the formulation.
A U.S. drug discovery biotech company based in Los Altos, California.
The impact on results for the current fiscal year will be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Alto-101 (schizophrenia treatment, PDE4 inhibitor transdermal patch) |
| Counterparty | Alto Neuroscience, Inc. (listed on a New York securities market) |
| Counterparty overview | A U.S. drug discovery biotech company based in Los Altos, California. |
| Relationship with the Company | Alto-101 is being developed in partnership with Alto. We will discuss the detailed analysis of the trial results, including the possibility of improving the formulation. |
| Applicable area | Treatment of patients with schizophrenia and treatment related to cognitive function |
| Quantitative Effects | Primary endpoint theta-band measure: n=83, d=0.34, p=0.052. Subgroup with impaired cognitive function: n=59, d=0.44, p=0.03. |
| Impact on Business Performance | The impact on results for the current fiscal year will be minor. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although statistical significance was not achieved for the primary endpoint, certain electroencephalographic measures showed a trend toward improvement. Alto also announced its policy of prioritizing the allocation of resources to Alto-207, its lead pipeline candidate.